Prot #CLDK378AUS23: Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

Project: Research project

Project Details

StatusFinished
Effective start/end date9/17/1412/31/18

Funding

  • United BioSource LLC (Prot #CLDK378AUS23)
  • Novartis Pharmaceuticals Corporation (Prot #CLDK378AUS23)